abstract |
Abstract The present application relates to anti-PD-Li antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions 5 thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer. 9740125_1 (GHMatters) P96856.AU.1 |